These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33815487)

  • 1. The Effect of Sodium Glucose Cotransporter 2 Inhibitors From a Human Genetic Perspective.
    Liu XZ; Zhang H
    Front Genet; 2021; 12():658012. PubMed ID: 33815487
    [No Abstract]   [Full Text] [Related]  

  • 2. A selectivity study of sodium-dependent glucose cotransporter 2/sodium-dependent glucose cotransporter 1 inhibitors by molecular modeling.
    Xu J; Yuan H; Ran T; Zhang Y; Liu H; Lu S; Xiong X; Xu A; Jiang Y; Lu T; Chen Y
    J Mol Recognit; 2015 Aug; 28(8):467-79. PubMed ID: 25753971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.
    Xu B; Li S; Kang B; Fan S; Chen C; Li W; Chen J; He Z; Tang F; Zhou J
    Mol Biol Rep; 2023 Nov; 50(11):9637-9647. PubMed ID: 37819499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
    Khunti K; Aroda VR; Bhatt DL; Bozkurt B; Buse JB; Heerspink HL; Inzucchi SE; Lam CSP; Marx N; McMurray JJV; Solomon SD; Kosiborod MN
    Diabetes Obes Metab; 2022 Nov; 24(11):2071-2080. PubMed ID: 35801339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study.
    Siao WZ; Lin TK; Huang JY; Tsai CF; Jong GP
    Diab Vasc Dis Res; 2022; 19(3):14791641221098168. PubMed ID: 35549730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism.
    Tang J; Ye L; Yan Q; Zhang X; Wang L
    Front Pharmacol; 2022; 13():800490. PubMed ID: 35281930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk.
    Hu WS; Lin CL
    J Diabetes Complications; 2023 May; 37(5):108468. PubMed ID: 37043985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: A systematic review and meta-analysis of randomized controlled trials and cohort studies.
    Huang X; Dannya E; Liu X; Yu Y; Tian P; Li Z
    Diabetes Obes Metab; 2024 Mar; 26(3):1040-1049. PubMed ID: 38086546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
    Lam CSP; Ramasundarahettige C; Branch KRH; Sattar N; Rosenstock J; Pratley R; Del Prato S; Lopes RD; Niemoeller E; Khurmi NS; Baek S; Gerstein HC
    Circulation; 2022 Feb; 145(8):565-574. PubMed ID: 34775781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of risk factors associated with acute kidney injury in patients taking sodium-glucose cotransporter-2 inhibitors.
    Schumacher C; Chorpash A; Bolch C; Eagan K; Nimer S; Van Dril E
    Pharmacotherapy; 2024 Mar; 44(3):249-257. PubMed ID: 38131129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
    Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
    Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
    van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
    Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation.
    Lau D; Pannu N; Yeung RO; Scott-Douglas N; Klarenbach S
    CMAJ Open; 2023; 11(1):E101-E109. PubMed ID: 36720493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease.
    Wakisaka M; Nakamura K; Nakano T; Kitazono T
    J Endocr Soc; 2021 Aug; 5(8):bvab083. PubMed ID: 34195526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
    Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
    J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom.
    Alkabbani W; Shah BR; Zongo A; Eurich DT; Alsabbagh MW; Gamble JM
    Diabetes Obes Metab; 2023 Dec; 25(12):3490-3500. PubMed ID: 37563767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes.
    Kim Y; Babu AR
    Diabetes Metab Syndr Obes; 2012; 5():313-27. PubMed ID: 22977310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis.
    Chun HJ; Kim ER; Lee M; Choi DH; Kim SH; Shin E; Kim JH; Cho JW; Han DH; Cha BS; Lee YH
    Metabolism; 2023 Aug; 145():155612. PubMed ID: 37277060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.